{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:51:58Z","timestamp":1790092318387,"version":"4.0.1"},"reference-count":60,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"No funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.1080\/13543784.2024.2320703","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T04:24:17Z","timestamp":1708143857000},"page":"219-228","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs"],"prefix":"10.1080","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2139-1448","authenticated-orcid":false,"given":"Shilan","family":"Mozaffari","sequence":"first","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-6197","authenticated-orcid":false,"given":"Shekoufeh","family":"Nikfar","sequence":"additional","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]},{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-1209","authenticated-orcid":false,"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2016.1158099"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.1013935"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01116-z"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.794223"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.02.029"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30217-X"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-817"},{"issue":"1","key":"e_1_3_4_10_1","first-page":"S17","article-title":"Impairment in work productivity and health-related quality of life in patients with IBS","volume":"11","author":"Dean BB","year":"2005","unstructured":"Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11(1 Suppl):S17\u201326.","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.629026"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1767067"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01523-4"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.04.017"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17726087"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.01.010"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44807"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16663396"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0084-x"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S216056"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024361"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S123621"},{"key":"e_1_3_4_23_1","unstructured":"Study to explore the therapeutic effect of Eluxadoline in treating irritable bowel syndrome with diarrhea in children. Allergan: ClinicalTrials.gov; 2017 [cited 2023 Dec 18]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/results\/NCT03339128?view=results"},{"key":"e_1_3_4_24_1","volume-title":"Alosetron. StatPearls. Treasure island (FL) ineligible companies. Disclosure: franklin Kasmin declares no relevant financial relationships with ineligible companies: StatPearls publishing copyright \u00a9 2023","author":"Butt I","year":"2023","unstructured":"Butt I, Kasmin F. Alosetron. StatPearls. Treasure island (FL) ineligible companies. Disclosure: franklin Kasmin declares no relevant financial relationships with ineligible companies: StatPearls publishing copyright \u00a9 2023. StatPearls Publishing LLC; 2023."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.05.002"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1533456"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13491798"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13030-017-0093-9"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172846"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-017-0734-2"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-318160"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305989"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000727"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17426"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3562-6"},{"issue":"2","key":"e_1_3_4_36_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cgh.2023.02.014","article-title":"Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome","volume":"22","author":"Goodoory VC","year":"2023","unstructured":"Goodoory VC, Tuteja AK, Black CJ, et al. Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol: the official clini prac jou of the Ameri Gastro Asso. 2023;22(2): 243\u201351.","journal-title":"Clin Gastroenterol Hepatol: the official clini prac jou of the Ameri Gastro Asso"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000696"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13065"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.02.027"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2019.1.01"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310683"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1887719"},{"key":"e_1_3_4_43_1","unstructured":"A trial for new treatment of adult participants with irritable bowel syndrome. 4D pharma plc: ClinicalTrials.Gov. 2020 [cited 2023 Dec 18]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03721107?cond=A+Trial+for+New+Treatment+of+Adult+Participants+With+Irritable+Bowel+Syndrome.&draw=2&rank=1"},{"key":"e_1_3_4_44_1","unstructured":"Study to evaluate the efficacy safety and tolerability of BOS-589 in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Boston P: ClinicalTrials.gov; 2020 [cited 2023 Dec 18]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03977155?cond=NCT03977155&draw=1&rank=1"},{"key":"e_1_3_4_45_1","unstructured":"A study to investigate the effect of solabegron (GW427353) on gastrointestinal transit in healthy volunteers. GlaxoSmithKline: ClinicalTrials.gov; 2008 [cited 2023 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00401479?term=NCT00401479&rank=1"},{"key":"e_1_3_4_46_1","first-page":"131","article-title":"Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS)","volume":"20","author":"Kelleher DH","year":"2008","unstructured":"Kelleher DH, Hicks KJ, Cox DS, et al. Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2008;20:131.","journal-title":"Neurogastroenterol Motil"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.046"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14448"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002314"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaa089"},{"key":"e_1_3_4_51_1","unstructured":"Effect of Olorinab on gastrointestinal transit in patients with irritable bowel syndrome. Arena P: ClinicalTrials.gov; 2021 [cited 2023 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04655599?term=NCT04655599&rank=1"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14539"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.12.034"},{"key":"e_1_3_4_54_1","unstructured":"Irritable bowel syndrome (IBS) treatment with H1-receptor antagonists. KU Leuven: ClinicalTrials.gov; 2016 [cited 2023 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01144832?term=NCT01144832&rank=141"},{"key":"e_1_3_4_55_1","unstructured":"Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial. KU Leuven: ClinicalTrials.gov; 2023 [cited 2023 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01908465?term=NCT01908465&rank=1"},{"key":"e_1_3_4_56_1","unstructured":"Ebastine Versus Mebeverine in IBS Patients. KU Leuven: ClinicalTrials.gov; 2023 [cited 2023 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05815602?term=NCT05815602&rank=1"},{"key":"e_1_3_4_57_1","unstructured":"A comparison of the effects of ORP-101 versus placebo in adult patients with irritable bowel syndrome with diarrhea (IBS-D). OrphoMed I Ppd: ClinicalTrials.gov; 2021 [cited 2023 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04129619?term=NCT04129619&rank=1"},{"key":"e_1_3_4_58_1","unstructured":"Efficacy and safety of rifaximin with NAC in IBS-D. Cedars-Sinai Medical C Bausch Health Ireland L: ClinicalTrials.gov; 2021 [cited 2023 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04557215?term=Efficacy%20and%20Safety%20of%20Rifaximin%20With%20NAC%20in%20IBS-D&rank=1"},{"key":"e_1_3_4_59_1","unstructured":"Comparing the efficacy of nitazoxanide versus rifaximin in adult patients with irritable bowel syndrome without constipation. Sadat City U: ClinicalTrials.gov; 2023 [cited 2023 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05453916?intr=Comparing%20the%20Efficacy%20of%20Nitazoxanide%20Versus%20Rifaximin%20in%20Adult%20Patients%20With%20Irritable%20Bowel%20Syndrome%20Without%20Constipation.%20&rank=1"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131126"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1442434"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1559821"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2320703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:08:49Z","timestamp":1738202929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2320703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,3]]}},"alternative-id":["10.1080\/13543784.2024.2320703"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2320703","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}